The aim of this retrospective single-center study was to analyze the clinical characteristics and outcome of @entity1893 ( @entity1893 ) @entity1 with central nervous system (CNS) involvement and to identify prognostic factors for survival. We searched our hospital records for @entity1893 @entity1 diagnosed with CNS involvement from 1982 to 2004, and 43 @entity1 were identified. The median age was 63 years (range 23-88) and the median Karnofsky performance status was 55% (range 10-90). Treatment of @entity149 included intrathecal chemotherapy in 33 @entity1 (77%), systemic chemotherapy in 25 (58%), and radiotherapy in 16 (37%). Twenty-six @entity1 showed a CNS response. The median survival after CNS manifestation was 5 months (range 2 days-82.5+months). Nine @entity1 achieved long-term survival. Low @entity880 dehydrogenase (LDH) at CNS manifestation and a CNS response to therapy were favorable independent prognostic factors for survival in multivariate analysis (p = 0.051 and p < 0.0005, respectively), whereas a young age at initial diagnosis, initial CNS involvement, an initially normal LDH, and high-dose chemotherapy for CNS involvement were significant in univariate analysis. In conclusion, long-term survival can be achieved in @entity1 with secondary @entity149 . LDH at CNS manifestation and a CNS response to therapy were significantly associated with survival.

Retrospective study of prognostic factors in XXXX secondarily involving the central nervous system.

@entity1893 :: ('MESH:D008228', 'Disease') :: ['NHL', 'non-Hodgkin lymphoma'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity149 :: ('MESH:D002493', 'Disease') :: ['CNS lymphoma'] @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate']
@entity1893 :: (MESH:D008228,Disease) :: ['non-Hodgkin lymphoma']
